EXPERIMENTAL IMMUNOLOGY
The effect of kynurenic acid on the synthesis of selected cytokines by murine splenocytes – in vitro and ex vivo studies
More details
Hide details
Submission date: 2015-12-11
Acceptance date: 2016-01-04
Publication date: 2016-03-24
Cent Eur J Immunol 2016;41(1):39-46
KEYWORDS
ABSTRACT
Kynurenic acid (KYNA), a secondary product of the kynurenine pathway of tryptophan degradation, known mainly as an endogenous neuroprotectant, shows also immunotropic properties. Some quantities of KYNA are present in food and are effectively absorbed in the gastrointestinal tract. Since the spleen is an important target of dietary immunomodulators, the aim of the study was to determine the effect of exogenous KYNA on murine splenocytes.Splenocytes isolated from adult BALB/c mice were used in the study. Firstly, the effect of increasing KYNA concentrations (0-5 mM) on the viability, and proliferative and cytokine response (interleukin 1β [IL-1β], IL-6, IL-10, tumor necrosis factor α [TNF-α]) of murine splenocytes under in vitro conditions was determined. Then, proliferative and cytokine responses were determined in cells derived from animals receiving kynurenic acid in drinking water at concentrations of 2.5, 25, or 250 mg/l for 7-14 days. Cytokine levels were measured using commercial immunoassay (ELISA) kits, and cell viability and proliferation was determined with MTT reduction assay. Exogenous KYNA was characterised by a low level of cytotoxicity towards murine splenocytes, and was well tolerated by the animals receiving it in drinking water. As expected, it exhibited anti-inflammatory action towards the activated splenocytes, under both in vitro and ex vivo conditions. Surprisingly, however, KYNA itself influenced the activity of resting, non-stimulated cells, exerting an immunostimulant effect in vitro, and an immunosuppressive effect under ex vivo conditions. The obtained results indicate not only anti-inflammatory, but also more complex, immunomodulating properties of KYNA, which require more detailed investigation.
REFERENCES (29)
1.
Moroni F, Fossati S, Chiarugi A, et al. (2007): Kynurenic acid actions in brain and periphery. Int Congr Ser 1304: 305-313.
2.
Chen Y, Guillemin GJ (2009): Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2: 1-19.
3.
Kudo Y, Boyd CA, Sargent IL, et al. (2001): Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation. J Physiol 535: 207-215.
4.
Mándi Y, Vécsei L (2012): The kynurenine system and immunoregulation. J Neural Transm 119: 197-209.
5.
Terness P, Bauer TM, Röse L, et al. (2002): Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196: 447-457.
6.
Wang J, Simonavicius N, Wu X, et al. (2006): Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281: 22021-22028.
7.
Kaszaki J, Palásthy Z, Érczes D, et al. (2008): Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterol Motil 20: 53-62.
8.
Lugo-Huitrón R, Blanco-Ayala T, Ugalde-Muñiz P, et al. (2011): On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 33: 538-547.
9.
Maes M, Mihaylova I, Ruyter M, et al. (2007): The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 28: 826-831.
10.
Małaczewska J, Siwicki AK, Wójcik RM, et al. (2014): Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice. Cent Eur J Immunol 39: 6-13.
11.
Tiszlavicz Z, Németh B, Fülöp F, et al. (2011): Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor- (TNF-) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedebergs Arch Pharmacol 383: 447-455.
12.
DiNatale B, Murray IA, Schroeder JC, et al. (2010): Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 115: 89-97.
13.
Maaetoft-Udsen K, Shimoda LM, Frøkiær H, et al. (2012): Aryl hydrocarbon receptor ligand effects in RBL2H3 cells. J Immunotoxicol 9: 327-337.
14.
Paluszkiewicz P, Zgrajka W, Saran T, et al. (2009): High concentration of kynurenic acid in bile and pancreatic juice. Amino Acids 37: 637-641.
15.
Zgrajka W, Turska M, Rajtar G, et al. (2013): Kynurenic acid content in anti-rheumatic herbs. Ann Agric Environ Med 20: 800-802.
16.
Turski MP, Turska M, Zgrajka W, et al. (2009): Presence of kynurenic acid in food and honeybee products. Amino Acids 36: 75-80.
17.
Turski MP, Turska M, Paluszkiewicz P, et al. (2013): Kynurenic acid in the digestive system – new facts, new challenges. Int J Tryptophan Res 6: 47-55.
18.
Wejksza K, Rzeski W, Turski WA (2009): Kynurenic acid protects against the homocysteine-induced impairment of endothelial cells. Pharmacol Rep 61: 751-756.
19.
Mosmann T (1983): Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
20.
Małaczewska J, Siwicki AK, Wójcik R, et al. (2014): The in vitro effect of kynurenic acid on the rainbow trout (Oncorhynchus mykiss) leukocyte and splenocyte activity. Pol J Vet Sci 17: 453-458.
21.
Turski WA, Małaczewska J, Marciniak S, et al. (2014): On the toxicity of kynurenic acid in vivo and in vitro. Pharm Rep 66: 1127-1133.
22.
Klien C, Patte-Mensah C, Taleb O, et al. (2013): The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction. Neuropharmacology 70: 254-260.
23.
Di Serio C, Cozzi A, Angeli I, et al. (2005): Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol 25: 981-993.
24.
Małaczewska J, Siwicki AK, Wójcik R, et al. (2013): Effect of dietary administration of kynurenic acid on the activity of splenocytes of the rainbow trout (Oncorhynchus mykiss). Centr Eur J Immunol 38: 475-479.
25.
Kiank C, Zeden JP, Drude S, et al. (2010): Psychologial stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS One 5: e11825.
26.
Steiner L, Gold M, Mengel D, et al. (2014): The endogenous 7 nicotinic acetylcholine receptor antagonist kynurenic acid modulates amyloid--induced inflammation in BV-2 microglial cells. J Neurol Sci 344: 94-99.
27.
Moroni F, Cozzi A, Sili M, et al. (2012): Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm 119: 133-139.
28.
Varga G, Erces D, Fazekas B, et al. (2010): N-methyl-D-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat. Neurogastroenterol Motil 22: 217-225.
29.
Stone TW, Stoy N, Darlington LG (2013): An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 34: 136-143.